Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Disease Reports
thrombasthenia
MeSH D013915 - thrombasthenia
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D025861:
Inherited blood coagulation disorders
27 Companies
2 Drugs
$
Success rate
D006474:
Hemorrhagic disorders
1 Company
1 Drug
$
Success rate
D001791:
Blood platelet disorders
0 Companies
0 Drugs
Success rate
D013915:
Thrombasthenia
1 Company
1 Drug
$
Success rate
Events Timeline
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
Novo Nordisk
Eptacog alfa (activated)
NovoSeven
1996-02-23
Clinical Trials
Historical Success Rate
Phase 1
33
%
1/3
Phase 2
0
%
0/8
Phase 3
100
%
1/1
Approved:
1
Overall Success rate:
0%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Novo Nordisk
Eptacog alfa (activated)
,
Coagulation factor viia recombinant human
,
Rfviia
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use